Edgestream Partners L.P. Invests $1.10 Million in Bruker Co. (NASDAQ:BRKR)

Edgestream Partners L.P. acquired a new stake in Bruker Co. (NASDAQ:BRKR - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,908 shares of the medical research company's stock, valued at approximately $1,099,000.

A number of other large investors have also made changes to their positions in the stock. First Horizon Advisors Inc. boosted its holdings in shares of Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock worth $25,000 after purchasing an additional 218 shares during the last quarter. UMB Bank n.a. grew its holdings in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock valued at $46,000 after buying an additional 354 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new position in shares of Bruker during the 2nd quarter valued at about $52,000. GAMMA Investing LLC lifted its holdings in shares of Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company's stock worth $60,000 after acquiring an additional 388 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in Bruker by 20.0% in the second quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company's stock valued at $63,000 after purchasing an additional 165 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.

Insider Buying and Selling

In other news, CEO Frank H. Laukien acquired 100,000 shares of the company's stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the acquisition, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.30% of the company's stock.

Bruker Stock Down 1.7 %

Bruker stock traded down $1.02 during midday trading on Thursday, hitting $58.48. 1,286,459 shares of the stock were exchanged, compared to its average volume of 1,114,691. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The company has a 50 day moving average price of $60.08 and a two-hundred day moving average price of $63.64. The firm has a market cap of $8.87 billion, a P/E ratio of 28.61, a P/E/G ratio of 3.86 and a beta of 1.18. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business had revenue of $864.40 million during the quarter, compared to analysts' expectations of $866.46 million. During the same period in the prior year, the company posted $0.74 EPS. The company's revenue for the quarter was up 16.4% on a year-over-year basis. On average, sell-side analysts predict that Bruker Co. will post 2.4 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.34%. Bruker's payout ratio is 9.62%.

Analyst Ratings Changes

A number of research firms have weighed in on BRKR. Wells Fargo & Company cut their price target on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 6th. Wolfe Research cut Bruker from an "outperform" rating to a "peer perform" rating in a report on Monday, September 30th. Barclays dropped their price target on Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. TD Cowen reduced their price objective on Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a research note on Wednesday, November 6th. Finally, Citigroup dropped their target price on shares of Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Bruker currently has a consensus rating of "Moderate Buy" and an average price target of $79.36.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.